RARS2

Across TCGA pan-cancer cohorts, RARS2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RARS2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RARS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RARS2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

UCEC, PDAC, and HNSC are the cancer types where RARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.941	0.497	.006	16	view →
PDAC	OS	Median	IV	0.381	0.951	.006	15	view →
HNSC	DFS	Tertile	II,III,IV	0.827	0.592	.029	12	view →
LSCC	OS	Median	II,III,IV	1.000	0.905	.023	7	view →
CCRCC	DFS	Quartile	III,IV	0.163	0.904	.038	4	view →
LUAD	OS	Median	III,IV	0.796	0.410	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RARS2–UCEC (DFS)

Open the UCEC breakdown →